^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gimeracil +oteracil +tegafur +folinic acid (TAS-118)

    i
    Other names: TAS-118, TAS 118
    Associations

    News

    Trials
    Company:
    Otsuka
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study. (PubMed, Gastric Cancer)
    Perioperative chemotherapy with TAS-118 plus oxaliplatin with D2 gastrectomy is feasible.
    Journal • Metastases
    |
    oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur) • gimeracil +oteracil +tegafur +folinic acid (TAS-118)
    over3years
    S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. (PubMed, Lancet Oncol)
    TAS-118 plus oxaliplatin showed a clinically meaningful improvement in efficacy compared with S-1 plus cisplatin, and could be considered a new first-line treatment option for advanced gastric cancer in Asian patients.
    Clinical • P3 data • Clinical Trial,Phase III • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    cisplatin • oxaliplatin • leucovorin calcium • gimeracil +oteracil +tegafur +folinic acid (TAS-118)
    almost4years
    SOLAR: Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer (clinicaltrials.gov)
    P3, N=711, Completed, Taiho Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    cisplatin • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • gimeracil +oteracil +tegafur +folinic acid (TAS-118)
    almost4years
    Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy? (PubMed, Future Oncol)
    No abstract available
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • oxaliplatin • gimeracil +oteracil +tegafur +folinic acid (TAS-118)